Clinical profile of saruplase: Angiographic findings

International Journal of Clinical Practice, Supplement

Volumn , Issue 99, 1998, Pages 9-15

  Meyer, J ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; FIBRINOLYTIC AGENT; HEPARIN; SARUPLASE; STREPTOKINASE; RECOMBINANT PROTEIN; UROKINASE;

ANGIOGRAPHY; BLOOD FLOW; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DOSE CALCULATION; DRUG EFFICACY; FIBRINOLYSIS; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; ORGAN PERFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ANGIOCARDIOGRAPHY; FIBRINOLYTIC THERAPY; METHODOLOGY; RECURRENT DISEASE; REVIEW;

ASPIRIN; CLINICAL TRIALS; CORONARY ANGIOGRAPHY; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; MYOCARDIAL INFARCTION; RECOMBINANT PROTEINS; RECURRENCE; THROMBOLYTIC THERAPY; URINARY PLASMINOGEN ACTIVATOR;

EID: 0032216636     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (18)

1. Gruppo italiano per lo studio della streptochinasi nell infarto miocardio (GISSI). Long-term effects of intravenous thrombolysis in acute myocardial infarction: Final report of GISSI study. Lancet 1987; ii: 871-874.
2. Simoons ML, Vos J, Tijssen JGP et al. Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the University Cardiology Institute of the Netherlands. J Am Coll Cardiol 1989; 14: 1609-1615.
3. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682.
4. Van de Werf F, Vanhaeke J, de Geest H et al. Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction. Circulation 1986; 74: 1066-1070.
5. Diefenbach C, Erbel R, Pop T et al. Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction. Am J Cardiol 1988; 61: 966-970.
6. Gore JM, Sloan M, Price TR et al. Intracerebral haemorrhage, cerebral infarction, and subdural haematoma after acute myocardial infarction and thrombolytic therapy in the thrombolysis in myocardial infarction study. Circulation 1991; 83: 448-459.
7. PRIMI trial study group. Randomised double-blind trial of recombinant prourokinase against streptokinase in acute myocardial infarction. Lancet 1989; i: 863-868.
8. Bär FW, Meyer J, Vermeer F et al. Early patency and reocclusion: comparison of saruplase and alteplase in acute myocardial infarction. Results of the randomized, multicentre SESAM study. Am J Cardiol 1997; 79: 727-732.
9. Tebbe U, Windeler J, Boesl I et al. Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study). J Am Coll Cardiol 1995; 26: 365-373.
10. Bär FW, Meyer J, Boland J et al. Bolus administration of saruplase in Europe (BASE), a pilot study in patients with acute myocardial infarction. J Thromb Thrombolysis 1998; 6: 147-153.
11. Belgian saruplase alteplase trial group. Effects of alteplase and saruplase on haemostatic variables: a single-blind, randomised trial in patients with acute myocardial infarction (SAT). Coron Artery Dis 1991; 2: 349-355.
12. Michels R, Hoffmann H, Windeler J et al. A double-blind multicentre comparison of the efficacy and safety of saruplase and urokinase in the treatment of acute myocardial infarction: Report of the SUTAMI study group. J Thromb Thrombolysis 1995; 2: 117-124.
13. Neuhaus K-L, von Essen R, Tebbe U et al. Improved thrombolysis in acute myocardial infarction with front loaded administration of alteplase: results of the rtPA-APSAC Patency Study (TAPS). J Am Coll Cardiol 1992; 19: 885-891.
14. Ross AM, Lundergan C, Thompson M et al. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-1622.
15. Chesebro JH, Knatterud G, Roberts R et al Thrombolysis in myocardial infarction (TIMI) trial, phase 1, a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987; 76: 142-154.
16. Neuhaus KL, Tebbe U, Gottwick M et al. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: Results of the German Activator Urokinase Study (GAUS). J Am Coll Cardiol 1988; 12: 581-587.
17. Verstraete M, Arnold AE, Brower RW et al. Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocciusion rate. Am J Cardiol 1987; 60: 231-237.
18. Topol EJ, Morris DC, Smalling RW et al. A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue type plasminogen activator (activase) in acute myocardial infarction. J Am Coll Cardiol 1987; 9: 1205-1213.